Batches of high blood pressure drug recalled due to ‘contamination’

But patients have been advised not to stop taking their medication without consulting a doctor.
A patient has their blood pressure checked (PA)
PA Wire
Ella Pickover9 August 2021

A number of batches of high blood pressure medication have been recalled due to “contamination with an impurity that could potentially increase the risk of cancer over time”.

The Medicines and Healthcare products Regulatory Agency (MHRA) issued a notice concerning 25 batches of Irbesartan-containing medicinal products.

Irbesartan is mostly used for treating high blood pressure but can also be used among some kidney patients.

The recall has only been issued to pharmacies and wholesalers so patients do not need to check their own medication.

If you’ve been taking one of the affected products, continue to take your medication. Speak with your doctor or pharmacist before stopping any treatment

MHRA

The medicines watchdog said that the recall is “precautionary” and that there is “no evidence” that the chemical impurity has caused any harm to patients.

And experts stressed that people should not abruptly stop taking their medication without consulting a pharmacist or doctor first.

They warned that suddenly stopping medication for high blood-pressure can be risky.

Dr Alison Cave, MHRA chief safety officer, said: “Patient safety is at the heart of what we do.

“We’re recalling batches of certain sartan-containing products as a precautionary measure while we continue our investigation.

“It’s important that healthcare professionals check their stock to quarantine and return these batches.

“If you’ve been taking one of the affected products, continue to take your medication.

“Speak with your doctor or pharmacist before stopping any treatment, they can address any concerns and can advise you on the best course of action.

“Previous recalls of these types of products in 2018, 2019 and June 2021 are part of an ongoing investigation.

“The MHRA is working with other medicines regulators on this issue.”

Create a FREE account to continue reading

eros

Registration is a free and easy way to support our journalism.

Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.

Your email address

Must be at least 6 characters, include an upper and lower case character and a number

You must be at least 18 years old to create an account

* Required fields

Already have an account? SIGN IN

By clicking Create Account you confirm that your data has been entered correctly and you have read and agree to our Terms of use , Cookie policy and Privacy policy .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in